BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24100449)

  • 1. Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model.
    Lascano V; Guadagnoli M; Schot JG; Luijks DM; Guikema JE; Cameron K; Hahne M; Pals S; Slinger E; Kipps TJ; van Oers MH; Eldering E; Medema JP; Kater AP
    Blood; 2013 Dec; 122(24):3960-3. PubMed ID: 24100449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TACI-dependent APRIL signaling maintains autoreactive B cells in a mouse model of systemic lupus erythematosus.
    Tran NL; Schneider P; Santiago-Raber ML
    Eur J Immunol; 2017 Apr; 47(4):713-723. PubMed ID: 28267197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
    Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
    Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated progression of chronic lymphocytic leukemia in Eμ-TCL1 mice expressing catalytically inactive RAG1.
    Nganga VK; Palmer VL; Naushad H; Kassmeier MD; Anderson DK; Perry GA; Schabla NM; Swanson PC
    Blood; 2013 May; 121(19):3855-66, S1-16. PubMed ID: 23502221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms in genes of the BAFF/APRIL system may constitute risk factors of B-CLL--a preliminary study on a Polish population.
    Jasek M; Wagner M; Sobczynski M; Wolowiec D; Kuliczkowski K; Woszczyk D; Kielbinski M; Kusnierczyk P; Frydecka I; Karabon L
    Tissue Antigens; 2015 Oct; 86(4):279-84. PubMed ID: 26268376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.
    Greene JT; Mani R; Ramaswamy R; Frissora F; Yano M; Zapolnik K; Harrington B; Wasmuth R; Tran M; Mo X; McKenna M; Rangnekar VM; Byrd JC; Bondada S; Muthusamy N
    Blood Adv; 2019 Apr; 3(8):1255-1266. PubMed ID: 30987970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.
    Motiwala T; Kutay H; Zanesi N; Frissora FW; Mo X; Muthusamy N; Jacob ST
    Leukemia; 2015 Jun; 29(6):1350-9. PubMed ID: 25482129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TACI expression and signaling in chronic lymphocytic leukemia.
    Mamara A; Germenis AE; Kompoti M; Palassopoulou M; Mandala E; Banti A; Giannakoulas N; Speletas M
    J Immunol Res; 2015; 2015():478753. PubMed ID: 25950010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression.
    Enzler T; Kater AP; Zhang W; Widhopf GF; Chuang HY; Lee J; Avery E; Croce CM; Karin M; Kipps TJ
    Blood; 2009 Nov; 114(20):4469-76. PubMed ID: 19755673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.
    Bresin A; Callegari E; D'Abundo L; Cattani C; Bassi C; Zagatti B; Narducci MG; Caprini E; Pekarsky Y; Croce CM; Sabbioni S; Russo G; Negrini M
    Oncotarget; 2015 Aug; 6(23):19807-18. PubMed ID: 26090867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation.
    Efanov A; Zanesi N; Nazaryan N; Santanam U; Palamarchuk A; Croce CM; Pekarsky Y
    Leukemia; 2010 May; 24(5):970-5. PubMed ID: 20357824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APRIL is overexpressed in cancer: link with tumor progression.
    Moreaux J; Veyrune JL; De Vos J; Klein B
    BMC Cancer; 2009 Mar; 9():83. PubMed ID: 19291294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients.
    Öztürk S; Paul Y; Afzal S; Gil-Farina I; Jauch A; Bruch PM; Kalter V; Hanna B; Arseni L; Roessner PM; Schmidt M; Stilgenbauer S; Dietrich S; Lichter P; Zapatka M; Seiffert M
    Leukemia; 2022 Feb; 36(2):464-475. PubMed ID: 34417556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice.
    Zanesi N; Aqeilan R; Drusco A; Kaou M; Sevignani C; Costinean S; Bortesi L; La Rocca G; Koldovsky P; Volinia S; Mancini R; Calin G; Scott CP; Pekarsky Y; Croce CM
    Cancer Res; 2006 Jan; 66(2):915-20. PubMed ID: 16424025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state.
    Herling M; Patel KA; Khalili J; Schlette E; Kobayashi R; Medeiros LJ; Jones D
    Leukemia; 2006 Feb; 20(2):280-5. PubMed ID: 16341048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APRIL promotes breast tumor growth and metastasis and is associated with aggressive basal breast cancer.
    García-Castro A; Zonca M; Florindo-Pinheiro D; Carvalho-Pinto CE; Cordero A; Gutiérrez del Fernando B; García-Grande A; Mañes S; Hahne M; González-Suárez E; Planelles L
    Carcinogenesis; 2015 May; 36(5):574-84. PubMed ID: 25750171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism.
    Grioni M; Brevi A; Cattaneo E; Rovida A; Bordini J; Bertilaccio MTS; Ponzoni M; Casorati G; Dellabona P; Ghia P; Bellone M; Calcinotto A
    Blood Adv; 2021 Jul; 5(14):2817-2828. PubMed ID: 34269799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts.
    Bossen C; Cachero TG; Tardivel A; Ingold K; Willen L; Dobles M; Scott ML; Maquelin A; Belnoue E; Siegrist CA; Chevrier S; Acha-Orbea H; Leung H; Mackay F; Tschopp J; Schneider P
    Blood; 2008 Feb; 111(3):1004-12. PubMed ID: 17942754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of caveolin-1 leads to delayed development of chronic lymphocytic leukemia in Eμ-TCL1 mouse model.
    Shukla A; Cutucache CE; Sutton GL; Pitner MA; Rai K; Rai S; Opavsky R; Swanson PC; Joshi SS
    Exp Hematol; 2016 Jan; 44(1):30-7.e1. PubMed ID: 26435347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L.
    Cols M; Barra CM; He B; Puga I; Xu W; Chiu A; Tam W; Knowles DM; Dillon SR; Leonard JP; Furman RR; Chen K; Cerutti A
    J Immunol; 2012 Jun; 188(12):6071-83. PubMed ID: 22593611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.